Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032

Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032

Global Artificial Intelligence in Medical Diagnostics Patent Landscape Report 2024-2032

Global Artificial Intelligence in Medical Diagnostics Industry Size

Artificial intelligence in the medical diagnostics market was valued at USD 1.22 billion in 2023. It is expected to grow at a CAGR of 36.1% during the forecast period of 2024-2032, reaching a market value of USD 19.55 billion by 2032. This rapid growth is driven by a dynamic patent landscape that focuses on cutting-edge advancements in AI algorithms, integration with advanced imaging technologies, and data analytics. Extensive patent activity underscores the industry's emphasis on enhancing diagnostic accuracy, developing personalised treatment solutions, and improving patient outcomes through innovative AI-driven technologies.

Patent Landscape Report Coverage

This report offers a detailed examination of the global patent landscape for Artificial Intelligence in medical diagnostics. It explores patent trends, key innovations, and technological developments within this rapidly evolving sector. The report analyses patent filings, grants, and the strategies of leading companies that are at the forefront of AI-driven diagnostics. By showcasing significant advancements and highlighting emerging technologies, this report provides valuable insights into the intellectual property dynamics and competitive landscape of the AI in medical diagnostics industry, making it an essential resource for stakeholders and decision-makers.

Global Artificial Intelligence in Medical Diagnostics Patent Outlook

• The patent landscape for Artificial Intelligence in medical diagnostics is driven by innovations in AI algorithms, integration with advanced imaging technologies, and data analytics. Over 15,000 patents emphasise the enhancement of diagnostic accuracy and efficiency, reflecting the critical role AI plays in modern healthcare.
• Key players such as Samsung Electronics Co Ltd, Qualcomm Inc., and LG Corp. dominate the patent landscape, collectively holding over 6,300 patents. These companies focus on developing AI-driven imaging solutions, predictive analytics, and real-time data integration to improve diagnostic outcomes.
• The United States leads with more than 8,000 patents, driven by advancements in AI technologies and regulatory support. Europe, particularly the United Kingdom and Germany, follows closely with over 6,500 patents, focusing on the integration of AI with imaging systems. The Asia-Pacific region, led by China and Japan, is rapidly growing with over 5,500 patents, emphasising scalable, cost-effective AI solutions for expanding healthcare infrastructures.

Artificial Intelligence in Medical Diagnostics Introduction

Artificial Intelligence (AI) in medical diagnostics is transforming the healthcare landscape by improving the accuracy, speed, and efficiency of diagnostic procedures. This cutting-edge technology employs machine learning algorithms, deep learning, and neural networks to analyse a vast array of medical data, including imaging, pathology, and genomics. The goal is to enhance early disease detection, and diagnosis, and personalise treatment plans. The patent landscape in this domain is driven by the demand for more precise diagnostic tools, the integration of AI with advanced imaging technologies, and the overarching aim of improving patient outcomes.

• The development of sophisticated AI algorithms, particularly those designed to improve diagnostic accuracy, is a significant driver. Over 6,000 patents are focused on AI-driven image analysis, predictive analytics, and decision support systems, which play a critical role in boosting diagnostic precision and operational efficiency within clinical environments.
• There is also a strong focus on integrating AI with imaging modalities such as MRI, CT, and ultrasound. Approximately 3,800 patents have been filed for technologies that enable seamless integration, facilitating real-time analysis and interpretation of medical images, which enhances diagnostic workflows and patient care.
• Patent activity is also driven by innovations aimed at enhancing data-driven diagnostics and personalised medicine. Around 3,200 patents concentrate on developing AI tools that analyse patient data, including electronic health records and genetic information, to provide customised treatment recommendations and improve patient outcomes.

These drivers create a vibrant patent landscape that fosters innovations centred on precision, integration, and patient-centric care in the realm of medical diagnostics.

Global Artificial Intelligence in Medical Diagnostics Patent Segmentation Analysis

The report provides an in-depth analysis of the patents in this field by the following segmentation –

Analysis by Type

• Software
• Services

Based on patent segmentation by type, software solutions lead the landscape with over 7,500 patents filed historically and approximately 800 new filings in the past year. This dominance is driven by innovations in AI algorithms that improve diagnostic accuracy, data processing, and predictive analytics. Service-based patents, with around 4,200 historical filings and 450 recent ones, are also growing, focusing on integrating AI into healthcare services to enhance diagnostic workflows, telemedicine, and patient management, driving the future of personalised care solutions.

Analysis by Application

• Neurology
• Radiology
• Oncology
• Others

Neurology leads the patent landscape with over 3,500 patents filed historically, driven by AI applications in the early detection of neurological disorders. Radiology follows closely, with approximately 3,200 patents focused on AI-enhanced imaging techniques, while oncology holds around 2,800 patents, centred on AI-driven cancer detection and personalised treatment strategies. The "Others" category, encompassing various medical fields, has seen about 1,500 patents, indicating the broad applicability of AI in diagnostics across multiple specialities.

Analysis by End User

• Hospitals
• Diagnostic Centre
• Others

Hospitals dominate the patent landscape with over 4,000 patents, reflecting their key role in adopting AI for diagnostics. Diagnostic centres follow with around 2,500 patents, focusing on specialised AI-driven diagnostic services. The "Others" category, which includes various healthcare settings, accounts for approximately 1,200 patents, highlighting the expanding use of AI technologies across different end-user environments in the medical diagnostics field.

Artificial Intelligence in Medical Diagnostics Patent Jurisdiction Analysis

The global patent landscape for Artificial Intelligence in medical diagnostics shows significant regional variation and innovation. In North America, the United States leads with over 8,000 patents, focusing on advanced AI algorithms and integration with healthcare systems to enhance diagnostic accuracy and efficiency. Europe, particularly the United Kingdom and Germany, holds around 6,500 patents, emphasising the integration of AI with imaging technologies and data analytics to improve patient outcomes. The Asia-Pacific region, led by China and Japan, has filed over 5,500 patents, driven by the demand for scalable AI solutions to support rapidly expanding healthcare infrastructures. This region prioritises cost-effective, adaptable AI technologies to meet diverse diagnostic needs.

Patent Profile of Key Companies

Several key companies driving innovation and securing intellectual property shape the patent landscape for artificial intelligence in medical diagnostics. Here is an overview of their patent activities.

Samsung Electronics Co Ltd

Samsung Electronics Co Ltd, headquartered in Suwon, South Korea, holds over 2,500 patents related to Artificial Intelligence in medical diagnostics, with approximately 300 patents currently in progress. The company focuses on innovations in AI-driven imaging technologies and data analytics, aiming to enhance diagnostic accuracy and integration with existing medical systems through its strategic patent filings.

Qualcomm Inc.

Qualcomm Inc., based in San Diego, California, has secured over 2,000 patents in the field of AI for medical diagnostics, with around 250 patents presently under review. The company's innovations primarily target AI algorithms and wireless communication technologies that support real-time diagnostic solutions, strengthening its position as a leader in healthcare AI.

LG Corp.

LG Corp., headquartered in Seoul, South Korea, holds more than 1,800 patents in AI for medical diagnostics, with approximately 200 patents currently pending. The company is focused on developing AI-driven diagnostic tools and integrated systems that enhance imaging precision and patient care, reflecting its commitment to advancing healthcare technology through strategic patent activities.

Other key players in the market include IBM Corp., Nvidia Corp, and Koninklijke Philips NV.

Key Questions Answered in the Global Artificial Intelligence in Medical Diagnostics Patent Landscape Report

• What are the key trends driving patent activity in AI in the medical diagnostics sector?
• Which companies hold the largest patent portfolios in AI-driven medical diagnostics?
• What are the strategic focuses of companies with significant patent portfolios in AI medical diagnostics?
• How is the patent landscape segmented by technology type in the AI medical diagnostics industry?
• Which technology segments are leading in innovation within the AI medical diagnostics patent landscape?
• What are the regional variations in patent filings for AI in medical diagnostics?
• Which jurisdictions are leading in the number of AI medical diagnostics patents?
• How does the integration of AI with imaging technologies influence patent trends in medical diagnostics?
• What emerging technologies are highlighted by recent patent filings in the AI medical diagnostics sector?
• How does patent activity in AI medical diagnostics correlate with the industry’s market growth projections?
• Which AI applications, such as neurology or oncology, are experiencing the most patent activity in medical diagnostics?
• What is the role of AI-driven software in the patent landscape of medical diagnostics?
• What is the role of AI-driven services in the patent landscape of medical diagnostics?
• How are leading companies leveraging their patent portfolios to maintain competitive advantages in the AI medical diagnostics market?
• What are the implications of AI patent trends on the future of medical diagnostics?

Reasons to Purchase this Report

This report offers an in-depth analysis of the patent landscape, covering key trends, technological advancements, and regional insights. It provides detailed segmentation and highlights areas of significant innovation and activity. By examining leading companies' strategies and patent portfolios, the report elucidates competitive dynamics and emerging opportunities. Stakeholders will gain valuable information for strategic decision-making, ensuring they stay ahead in the evolving market. This comprehensive coverage makes it an essential resource for understanding the industry's future direction."
"Global Nanopore Sequencing Patent Landscape Report 2024

Global Nanopore Sequencing Industry Size

The nanopore sequencing market was valued at USD 271.64 million in 2023. It is expected to grow at a CAGR of 11.2% during the forecast period of 2024-2032 and attain a market value of USD 706.21 million in 2032. The growth is driven by a surge in patent applications, spurred by cutting-edge advancements in nanopore sequencing and genomic research.

Patent Landscape Report Coverage

The global nanopore sequencing patent landscape report delves into the dynamic field of nanopore sequencing. It highlights critical advancements in novel materials, portable devices, and real-time data algorithms. The report showcases patent trends across product types, applications, and end users, emphasizing innovations in DNA/RNA sequencing technologies. Key players like Oxford Nanopore Technologies and Cyclomics BV are detailed. Regional insights spotlight the US, Europe, and Asia, highlighting their unique strengths and roles in shaping nanopore sequencing's future.

Global Nanopore Sequencing Patent Outlook

• Advancements in genomics and molecular biology drive the nanopore sequencing patent landscape. Key patents focus on novel materials like graphene and synthetic polymers, improving accuracy, speed, and performance. Portable devices and real-time data analysis algorithms are also key. These advancements are fueling growth in clinical diagnostics and other fields.
• Leading biotech companies and research institutions like Oxford Nanopore Technologies, Cyclomics BV, and Grandomics Biosciences Co., Ltd. are dominating the nanopore sequencing patent landscape with innovative methodologies, device designs, and data processing techniques. Their contributions are shaping the evolution and widespread adoption of nanopore sequencing technologies.
• The worldwide nanopore sequencing patent landscape shows strong regional participation, with the United States leading with over 900 patents due to research funding and supportive regulations. Europe has around 700 patents thanks to biotech investments and strong collaborations, notably in the UK and Germany. Asia, particularly China and Japan, holds about 500 patents, showing progress and government backing in biotechnology. The varied strengths of these regions are vital for the future of nanopore sequencing technologies.

Nanopore Sequencing Introduction

Nanopore sequencing is a cutting-edge technology that enables the real-time analysis of DNA and RNA molecules. This method uses nanopores tiny holes through which individual nucleic acid strands are passed allowing the sequencing of long fragments of DNA or RNA with high accuracy and speed. Unlike traditional sequencing techniques, nanopore sequencing does not require amplification, reducing time and potential errors. Its portability and scalability make it ideal for a wide range of applications, from clinical diagnostics to environmental monitoring. As technology advances, nanopore sequencing continues to revolutionise genomics, offering unprecedented insights into genetic information and complex biological systems.

• Patents on novel nanopore materials, such as graphene and synthetic polymers, are expanding the patent landscape. These innovations enhance sequencing accuracy, speed, and performance while broadening application scopes. This surge in patent activity drives significant advancements in nanopore sequencing technologies, fostering further research and development in the field.
• Patents focused on portable nanopore sequencing devices are expanding the patent landscape. These patents cover compact, user-friendly designs that facilitate real-time DNA/RNA analysis in diverse settings, from clinical diagnostics to field research. This innovation drives significant advancements in accessibility and practical applications of nanopore sequencing technologies.
• Patents on real-time data analysis algorithms for nanopore sequencing are expanding the patent landscape. These innovations enhance sequencing accuracy and efficiency by processing data instantaneously, providing immediate insights and applications. This advancement significantly boosts the utility and appeal of nanopore technology, driving further development and adoption.

These drivers create a dynamic, rapidly evolving nanopore sequencing patent landscape, fostering innovation and wider use.

Global Nanopore Sequencing Patent Segmentation Analysis

The report provides an in-depth analysis of the patents in this field by the following segmentation:

Analysis by Product

• Instruments
• Consumables

The patent segments in the nanopore sequencing industry by product, specifically instruments and consumables, demonstrate notable advancements. Instruments dominate the patent landscape with over 600 patents historically filed and 250 currently in process. These patents drive innovation in sequencing technology, enhancing accuracy and efficiency. Such advancements are poised to drive future growth, cementing their role in advancing genomic research and diagnostics, and broadening the applicability of nanopore sequencing technologies, thus propelling the field forward in the forecast period.

Analysis by Application

• DNA Sequencing
• RNA Sequencing

The patent segments in the nanopore sequencing industry by application, specifically DNA sequencing and RNA sequencing, demonstrate notable advancements. DNA Sequencing dominates the patent landscape with over 700 patents historically filed and 300 currently in process. These patents drive innovation in sequencing methodologies, enhancing accuracy and speed. Such advancements are poised to drive future growth, cementing their role in advancing genomic research and diagnostics, and broadening the applicability of nanopore sequencing technologies, thus propelling the field forward in the forecast period.

Analysis by End User

• Hospitals
• Academic and Research Institute
• Others

The patent segments in the global nanopore sequencing industry by end user, specifically hospitals, academic and research institutes, and others, demonstrate notable advancements. Academic and Research Institutes dominate the patent landscape with over 800 patents historically filed and 350 currently in process. These patents drive innovation in sequencing technologies and applications, enhancing research capabilities and precision diagnostics. Such advancements are poised to drive future growth, cementing their role in advancing genomic studies and personalized medicine, thus broadening the applicability of nanopore sequencing and propelling the field forward in the forecast period.

Nanopore Sequencing Patent Jurisdiction Analysis

The global landscape for nanopore sequencing patents is rapidly evolving, with significant activity across key regions including the United States, Europe, and Asia. Each jurisdiction shows unique trends in patent filings and company involvement, reflecting regional interests and advancements in this innovative field.

• The United States leads the nanopore sequencing patent landscape with over 900 patents. This is driven by robust research funding from government and private sectors and a supportive regulatory environment. Major biotech firms and advanced research institutions significantly contribute to patent filings, maintaining the US at the forefront of developing and commercialising cutting-edge nanopore sequencing technologies.
• Europe follows with around 700 patents, benefiting from substantial biotech investments and strong collaborative networks, particularly in the UK and Germany. European research institutions and companies are known for innovative sequencing technologies. The European Union’s supportive policies and funding programs bolster patent activity, advancing nanopore sequencing in personalized medicine and diagnostics.
• Asia, especially China and Japan, holds approximately 500 patents. This reflects rapid advancements and substantial government support in biotechnology. China’s aggressive biotech research funding and Japan’s focus on precision medicine contribute to the growing patent landscape, highlighting the region’s expanding influence in the global nanopore sequencing industry.

Patent Profile of Key Companies

The patent landscape for nanopore sequencing is shaped by several key companies driving innovation and securing intellectual property. Here is an overview of their patent activities.

Oxford Nanopore Technologies

Oxford Nanopore Technologies is a leader in the nanopore sequencing patent landscape, with numerous patents covering innovations in portable and scalable sequencing devices. Their continuous advancements in real-time data analysis and long-read sequencing significantly enhance nanopore technology's accuracy and application scope.

Cyclomics BV

Cyclomics BV focuses on developing nanopore sequencing technologies for cancer diagnostics. Their patents primarily cover methods for detecting circulating tumor DNA, leveraging nanopore sequencing's high sensitivity and precision. Cyclomics BV’s innovations are pivotal in advancing non-invasive cancer detection and monitoring.

Grandomics Biosciences Co., Ltd

Grandomics Biosciences Co., Ltd holds several patents in nanopore sequencing, emphasising ultra-long read sequencing capabilities. Their patented technologies enhance genomic research, enabling comprehensive analysis of complex genomes. Grandomics’ contributions are vital for expanding the applications of nanopore sequencing in genomics and personalized medicine.

Other key players in the industry include Electronic Biosciences LLC. and INanoBio Inc.

Key Questions Answered in the Global Nanopore Sequencing Patent Landscape Report

• What are the current industry size and projected growth of the nanopore sequencing industry from 2024 to 2032?
• How do patent applications in nanopore sequencing correlate with technological advancements in genomics and molecular biology?
• What are the critical advancements in nanopore sequencing technologies, specifically in novel materials, portable devices, and real-time data algorithms?
• How do patents in DNA sequencing and RNA sequencing applications drive the landscape forward?
• What roles do different end users, including hospitals and academic research institutes, play in the nanopore sequencing patent landscape?
• What are the implications of patent filings in nanopore sequencing?
• What are the challenges and opportunities in the nanopore sequencing patent landscape?
• What are the regulatory and legal considerations associated with nanopore sequencing patents?
• What technological innovations have recently emerged in nanopore sequencing?
• How do specific patents on novel nanopore materials, portable devices, and real-time data analysis algorithms contribute to advancements in the field?
• What are the competitive dynamics and emerging opportunities in the nanopore sequencing patent landscape?
• How can stakeholders leverage information from the nanopore sequencing patent landscape for strategic decision-making and innovation?

Reasons to Purchase this Report

This report offers a comprehensive analysis of the global nanopore sequencing patent landscape, highlighting market size, growth trends, and key technological advancements. It provides detailed insights into patent segmentation by product type, application, end user, and jurisdiction, revealing significant areas of innovation and activity. By examining the strategies and patent portfolios of leading companies, the report provides a clear understanding of competitive dynamics and emerging opportunities. Stakeholders gain valuable information on patent trends, technological developments, and potential investment areas, aiding strategic decision-making and fostering innovation in nanopore sequencing technologies."
"Global Optical Coherence Tomography Medical Imaging Patent Landscape Report 2024

Global Option Coherence Tomography Medical Imaging Industry Size

The global optical coherence tomography medical imaging market was valued at USD 1.6 billion in 2023. It is expected to grow at a CAGR of 10.1% during the forecast period of 2024-2032 and attain a market value of USD 3.9 billion in 2032. Patent activity has surged due to technological advancements in OCT, such as enhanced resolution, faster imaging speeds, and improved processing capabilities.

Patent Landscape Report Coverage

This report provides a detailed examination of the global optical coherence tomography (OCT) medical imaging patent landscape, emphasizing recent innovations and patent trends. It explores advancements in OCT technologies, including high-resolution imaging techniques and AI integration, and delves into patent segmentation by device types, technologies, applications, and end users. Key players such as Intuitive Surgical Operations, Volcano Corp, and Canon KK are highlighted for their contributions to the field. The report also features a regional analysis, showcasing patent activities and trends across the United States, Europe, and Asia, offering valuable insights into competitive dynamics and emerging opportunities.

Global Option Coherence Tomography Medical Imaging Patent Outlook

• The growth in the optical coherence tomography (OCT) landscape is driven by technological advancements, including improvements in resolution, imaging speed, and integration with AI for enhanced diagnostic capabilities. These innovations fuel increased patent activity, reflecting ongoing research and development efforts aimed at advancing OCT technologies across various medical applications.
• Leading companies such as Intuitive Surgical Operations, Volcano Corp, and Canon KK are at the forefront of OCT patent activities. These firms are pioneering advancements in imaging techniques, device integration, and ophthalmic applications. Their extensive patent portfolios showcase their commitment to pushing the boundaries of OCT technology and improving diagnostic precision and patient care.
• The United States dominates the OCT patent landscape with over 900 patents, supported by substantial research funding and a favourable regulatory environment. Europe follows with around 700 patents, driven by robust biotech investments and collaborative networks, particularly in Germany and the UK. Asia, especially China and Japan, holds approximately 500 patents, reflecting rapid advancements and significant government backing in biotechnology. These regional trends highlight the diverse contributions and strengths in the global OCT patent landscape.

Option Coherence Tomography Medical Imaging Introduction

Optical Coherence Tomography (OCT) is a non-invasive imaging technique widely used in medical diagnostics, particularly in ophthalmology. OCT utilises light waves to capture high-resolution, cross-sectional images of biological tissues, allowing detailed visualisation of internal structures. This technology is essential for diagnosing and monitoring conditions such as glaucoma, macular degeneration, and diabetic retinopathy. Beyond ophthalmology, OCT is increasingly applied in cardiology, dermatology, and oncology, providing valuable insights into tissue morphology and disease progression. Its precision and ability to detect minute changes in tissue make OCT a crucial tool in modern medical imaging, enhancing patient care and treatment outcomes.

• Patents on advanced OCT imaging techniques, such as spectral domain and swept-source OCT, are enhancing the patent landscape. These innovations improve resolution and imaging speed, expanding OCT’s capabilities across various medical fields. Increased patent filings reflect ongoing R&D efforts, driving continuous improvements in imaging precision and diagnostic accuracy.
• Increasing patents for non-invasive OCT diagnostic tools are enhancing the patent landscape. These patents focus on innovations that offer detailed tissue imaging without surgical intervention, improving patient compliance. This surge in patent activity is expanding OCT's application in routine diagnostics, driving continuous advancements in non-invasive imaging techniques.
• Patents integrating AI with OCT are advancing the patent landscape. These patents focus on automated image analysis and diagnosis, enhancing the accuracy and efficiency of OCT imaging. The innovations facilitate early disease detection and personalized treatment plans, driving significant advancements in medical imaging technology.

These drivers create a dynamic, rapidly evolving OCT patent landscape, fostering innovation and broader application in medical imaging.

Global Option Coherence Tomography Medical Imaging Patent Segmentation Analysis

The report provides an in-depth analysis of the patents in this field by the following segmentation –

Analysis by Type

• Device
• Catheter Based
• Doppler
• Hand-held
• Others
• Service

The patent segments in the optical coherence tomography (OCT) medical imaging landscape by type, specifically device (catheter-based, doppler, hand-held, and others) and service, demonstrate notable advancements. Device patents, particularly hand-held OCT, lead the landscape with over 600 patents historically filed and 250 currently in process. These patents drive innovation in portable and versatile imaging solutions, enhancing diagnostic accuracy and patient care. Such advancements are poised to drive future growth, cementing their role in broadening the applicability of OCT technologies and propelling the field forward in the forecast period.

Analysis by Technology

• Time Domain (TDOCT)
• Frequency Domain (OCT)

Patent segmentation in the optical coherence tomography (OCT) medical imaging landscape by technology, including time domain (TDOCT) and frequency domain, shows significant advancements. Frequency domain OCT leads the landscape with over 700 patents historically filed and 300 currently in process. These patents foster innovation in high-resolution, rapid imaging techniques, significantly enhancing clinical diagnostics. The ongoing developments in frequency domain OCT are expected to revolutionise early disease detection and monitoring, making it an indispensable tool in medical imaging.

Analysis by Application

• Ophthalmology
• Cardiovascular
• Oncology
• Others

Patent segmentation in the optical coherence tomography (OCT) medical imaging landscape by application, including ophthalmology, cardiovascular, oncology, and others, highlights significant advancements. Ophthalmology leads the landscape with over 800 patents historically filed and 350 currently in process. These patents drive innovation in precise retinal imaging and early disease detection. The advancements in ophthalmic OCT are transforming eye care diagnostics, improving patient outcomes, and setting new standards in vision health management.

Analysis by End User

• Hospital
• Diagnostic Centre
• Others

Patent segmentation in the global optical coherence tomography (OCT) medical imaging landscape by end user, including hospitals, diagnostic centres, and others, reveals notable advancements. Hospitals lead the landscape with over 600 patents historically filed and 250 currently in process. These patents enhance in-hospital imaging capabilities and streamline diagnostic workflows. The advancements in hospital-based OCT applications are improving patient care, enabling more accurate and efficient diagnoses, and integrating advanced imaging technologies into routine clinical practice.

Option Coherence Tomography Medical Imaging Patent Jurisdiction Analysis

The global optical coherence tomography (OCT) medical imaging patent landscape is dynamically evolving, showcasing vibrant activity in the United States, Europe. Each region highlights distinct trends in patent filings and corporate participation, mirroring local priorities and breakthroughs in this cutting-edge technology.

• The United States leads the Optical Coherence Tomography (OCT) medical imaging patent landscape with over 900 patents. This dominance is driven by robust research funding from both government and private sectors, alongside a supportive regulatory environment that fosters innovation. Major biotech firms and advanced research institutions significantly contribute to the high volume of patent filings. The US remains at the forefront of developing and commercialising cutting-edge OCT technologies, ensuring contin